The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $63.29

Today's change0.00 0.00%
Updated April 20 4:02 PM EDT. Delayed by at least 15 minutes.
 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $63.29

Today's change0.00 0.00%
Updated April 20 4:02 PM EDT. Delayed by at least 15 minutes.

Teva Pharmaceutical Industries Ltd closed at (U.S.)$63.29.

Shares have lost 4.14% over the last five days, but have gained 10.05% over the last year to date. This security has outperformed the S&P 500 by 11.83% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $63.29
  • High--
  • Low--
  • Bid / Ask(U.S.) $65.56 / (U.S.) $65.75
  • YTD % change+10.05%
  • Volume17,914
  • Average volume (10-day)8,037,955
  • Average volume (1-month)6,635,248
  • Average volume (3-month)5,306,562
  • 52-week range(U.S.) $47.36 to (U.S.) $68.75
  • Beta0.58
  • Trailing P/E17.75×
  • P/E 1 year forward12.26×
  • Forward PEG25.90×
  • Indicated annual dividend(U.S.) $1.36
  • Dividend yield2.14%
  • Trailing EPS(U.S.) $3.57
Updated April 20 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+15.03%

Based on its net profit margin of 15.03%, Teva Pharmaceutical Industries Ltd is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue5,1685,0585,0455,001
Total other revenue--------
Total revenue5,1685,0585,0455,001
Gross profit2,8892,8092,6612,697
Total cost of revenue2,2792,2492,3842,304
Total operating expense4,2263,9464,1204,029
Selling / general / administrative1,3261,2401,2111,269
Research & development379412344353
Depreciation / amortization--3717
Interest expense (income), net operating--------
Unusual expense (income)2424216986
Other operating expenses, total--------
Operating income9421,112925972
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax8721,028847891
Income after tax686868745748
Income tax, total186160102143
Net income687876748744
Total adjustments to net income--0----
Net income before extra. items687876748744
Minority interest-71334
Equity in affiliates8-5---8
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items687876748744
Inc. avail. to common incl. extra. items687876748744
Diluted net income689878748744
Dilution adjustment2200
Diluted weighted average shares861861857852
Diluted EPS excluding extraordinary itemsvalue per share0.801.020.870.87
Dividends per sharevalue per share0.320.340.350.34
Diluted normalized EPSvalue per share1.021.061.050.96